ArticleJournal of clinical microbiology2009
Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 89 citations in OpenAlex.
- Comparative performance of CMV IgM and IgG avidity assays for diagnosing a recent primary infection in the first trimester of pregnancy.Journal of clinical microbiology · 2026Article
- Maternal Cytomegalovirus Viral Load Correlates With the Risk of Congenital Infection and With Antiviral Therapy Response in Early Pregnancy.Open forum infectious diseases · 2026Article
- Cytomegalovirus Vertical Transmission Rate According to IgG Avidity Value and Valacyclovir Treatment of Maternal Primary Infection in the First Trimester of Pregnancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- CMV primary and non-primary infections among daycare workers, and development of strategies to prevent infection (EDUQ-CMV): a mixed-method study protocol.BMC infectious diseases · 2025Observational
- Reliability of CMV-IgG kinetics in the diagnosis of CMV primary infection: sensitivity, specificity, and clinical implications.Microbiology spectrum · 2025Article
- Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT.Blood advances · 2025Article
- Article
- An Overview of Cytomegalovirus Infection in Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
- Pitfalls in the Serological Evaluation of Maternal Cytomegalovirus Infection as a Potential Cause of Fetal and Neonatal Involvements: A Narrative Literature Review.Journal of clinical medicine · 2022Review
- Association Between First-Trimester Maternal Cytomegalovirus Infection and Stillbirth: A Prospective Cohort Study.Frontiers in pediatrics · 2022Article
- The Current Challenges in Developing Biological and Clinical Predictors of Congenital Cytomegalovirus Infection.International journal of molecular sciences · 2021Review
- Hygiene promotion might be better than serological screening to deal with Cytomegalovirus infection during pregnancy: a methodological appraisal and decision analysis.BMC infectious diseases · 2020Article
- Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.Clinical microbiology reviews · 2019Review
- Diagnosis of Human Immunodeficiency Virus Infection.Clinical microbiology reviews · 2019Review
- Potential Biomarkers for Predicting Congenital Cytomegalovirus Infection.International journal of molecular sciences · 2018Review
- Article
- Anti-cytomegalovirus immunoglobulin M titer for congenital infection in first-trimester pregnancy with primary infection: a multicenter prospective cohort study.Journal of perinatology : official journal of the California Perinatal Association · 2017Article
- Testing for Cytomegalovirus in Pregnancy.Journal of clinical microbiology · 2017Review
- Excluding Anti-cytomegalovirus Immunoglobulin M-Positive Cord Blood Units Has a Minimal Impact on the Korean Public Cord Blood Bank Inventory.Cell transplantation · 2017Article
- Evaluation of a standardised real-time PCR based DNA-detection method (Realstar®) in whole blood for the diagnosis of primary human cytomegalovirus (CMV) infections in immunocompetent patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A panel of new cytomegalovirus (CMV) assays for use on the Architect instrument has been developed, including a CMV avidity assay based on a new technology. The purpose of this study was to compare the performance characteristics of the fully automated CMV immunoglobulin M (IgM), IgG, and IgG avidity tests on the Architect instrument with those of other available assays. A total of 503 consecutive fresh patient serum specimens (routine serum specimens) and 96 serum specimens from 33 pregnant women with a recent CMV primary infection (seroconversion serum specimens) were tested for CMV IgM and IgG by the Architect (Abbott), Vidas (BioMérieux), and Enzygnost (Siemens) assays. The seroconversion sera and 100 preselected serum specimens IgM negative and IgG positive by the AxSYM assay were also tested by the IgG avidity tests on the Architect and Vidas instruments. The relative agreements for CMV IgM determination with routine sera between the Architect assay and the Vidas, Enzygnost, and AxSYM assays were 97%, 94%, and 93%, respectively, for the CMV IgM tests and 99%, 98%, and 98%, respectively, for the CMV IgG tests. The specificities of the CMV IgG avidity test were 98% for the Architect assay and 76% for the Vidas assay. No high CMV IgG avidity test results were found within the first 3 months after seroconversion by either of those assays. The correlation between the results of the newly developed CMV IgM and IgG tests on the Architect instrument with the Vidas and Enzygnost assays was excellent (> or = 94%). The CMV IgG avidity test reliably excluded patients with recent infections and showed an excellent specificity (98%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.